Samsung Bioepis Holdings, spun off from Samsung Biologics, will be relisted on the stock market on the 24th.
Korea Exchange (KRX) said on the 20th that it will list the common shares of Samsung Bioepis Holdings, which was spun off from Samsung Biologics, on the stock market on the 24th.
The number of listed shares is 24,883,049, and the par value is 2,500 won.
Samsung Bioepis Holdings, the newly established company through the spin-off, will operate as a holding company, managing the equity of subsidiaries such as Samsung Bioepis and EPIS NexLab and pursuing new investment businesses.
Samyang Biopharm, spun off from Samyang Holdings, will also be listed on the 24th.
The number of listed shares is 7,435,870, and the par value is 500 won.
Samyang Biopharm, the newly established company through the spin-off, is expected to operate businesses in the pharmaceutical and bio sector (pharmaceuticals, medical devices, new drug development, etc.).